Vemurafenib in Chinese patients with BRAFV600 mutation–positive unresectable or metastatic melanoma: an open-label, multicenter phase I study

被引:0
作者
Lu Si
Xiaoshi Zhang
Zhen Xu
Qiudi Jiang
Lilian Bu
Xuan Wang
Lili Mao
Weijiang Zhang
Nicole Richie
Jun Guo
机构
[1] Peking University Cancer Hospital & Institute,Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education)
[2] Sun Yat-sen University Cancer Center,undefined
[3] Roche Product Development in Asia Pacific,undefined
[4] Roche R&D Center China Ltd.,undefined
[5] Roche Innovation Center New York,undefined
[6] Genentech,undefined
[7] Inc.,undefined
来源
BMC Cancer | / 18卷
关键词
-positive; Advanced melanoma; Vemurafenib; China; Asia;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
相关论文
共 37 条
[1]  
Chi Z(2011)Clinical presentation, histology, and prognoses of malignant melanoma in ethnic Chinese: a study of 522 consecutive cases BMC Cancer 11 85-1463
[2]  
Li S(2015)Chinese guidelines on the diagnosis and treatment of melanoma (2015 edition) Ann Transl Med 3 322-1246
[3]  
Sheng X(2013)A phase II, randomized, double-blind, placebo-controlled multicenter trial of Endostar in patients with metastatic melanoma Mol Ther 21 1456-954
[4]  
Guo J(2011)Prognostic and clinicopathologic associations of oncogenic J Clin Oncol 29 1239-2147
[5]  
Qin S(2002) in metastatic melanoma Nature 417 949-100
[6]  
Liang J(2005)Mutations of the N Engl J Med 353 2135-2516
[7]  
Cui C(2012) gene in human cancer Eur J Cancer 48 94-332
[8]  
Mao L(2011)Distinct sets of genetic alterations in melanoma N Engl J Med 364 2507-111
[9]  
Chi Z(2014)Prevalence of BRAF V600E mutation in Chinese melanoma patients: large scale analysis of BRAF and NRAS mutations in a 432-case cohort Lancet Oncol 15 323-714
[10]  
Long GV(2014)For the BRIM-3 study group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation Cancer Chemother Pharmacol 73 103-666